Announcements

Updates on campus events, policies, construction and more.

close  

Information for Our Community

Whether you are part of our community or are interested in joining us, we welcome you to Washington University School of Medicine.

close  


Visit the News Hub

Foodborne fungus impairs intestinal wound healing in Crohn’s disease

Study in mice, people suggests new approaches to treating symptoms

by Tamara BhandariMarch 11, 2021

Getty Images

Eating is a dangerous business. Naturally occurring toxins in food and potentially harmful foodborne microbes can do a number on our intestines, leading to repeated minor injuries. In healthy people, such damage typically heals in a day or two. But in people with Crohn’s disease, the wounds fester, causing abdominal pain, bleeding, diarrhea and other unpleasant symptoms.

Researchers at Washington University School of Medicine in St. Louis and the Cleveland Clinic have discovered that a fungus found in foods such as cheese and processed meats can infect sites of intestinal damage in mice and people with Crohn’s and prevent healing. Moreover, treating infected mice with antifungal medication eliminates the fungus and allows the wounds to heal.

The findings, published March 12 in the journal Science, suggest that antifungal drugs and dietary changes are potential new approaches to improving intestinal wound healing and reducing symptoms of Crohn’s disease.

“We’re not suggesting that people stop eating cheese and processed meat; that would be going far beyond what we know right now,” said first author Umang Jain, PhD, an instructor in pathology & immunology at the School of Medicine. “What we know is that this foodborne fungus gets into inflamed, injured tissue and causes harm. We’re planning to perform a larger study in people to figure out if there’s a correlation between diet and the abundance of this fungus in the intestine. If so, it is possible dietary modulation could lower levels of the fungus and thereby reduce symptoms of Crohn’s disease.”

Crohn’s is a subtype of inflammatory bowel disease. As the name suggests, it is driven by chronic inflammation in the digestive tract and primarily treated with immunosuppressive medications. Crohn’s patients endure repeated cycles of gastrointestinal symptom flare-up and remission. During a flare, their digestive tracts are dotted with inflamed, open sores that can persist for weeks or even months.

To understand why intestinal ulcers take so long to heal in some people, Jain and senior author Thaddeus Stappenbeck, MD, PhD, formerly at Washington University and now at the Cleveland Clinic, studied mice whose intestines had been injured. By sequencing microbial DNA at the site of injury, they discovered that the fungus Debaryomyces hansenii was abundant in wounds but not in uninjured parts of the intestine.

People acquire the fungus through their food and drink, Jain said. D. hansenii is commonly found in all kinds of cheeses, as well as sausage, beer, wine and other fermented foods.

Further experiments showed that introducing the fungus into mice with injured intestines slowed down the healing process, and that eliminating D. hansenii with the antifungal drug amphotericin B sped it up.

People with Crohn’s disease carry the same fungus as the mice. Jain and Stappenbeck examined intestinal biopsies from seven people with Crohn’s disease and 10 healthy people. All seven of the patients harbored the fungus in their gut tissue, as compared with only one of the healthy people. In a separate analysis of 10 Crohn’s patients involving tissue samples of both inflamed and uninflamed areas of the gut, the researchers found the fungus in samples from all of the patients but only at sites of injury and inflammation.

“If you look at stool samples from healthy people, this fungus is highly abundant,” Jain said. “It goes into your body and comes out again. But people with Crohn’s disease have a defect in the intestinal barrier that enables the fungus to get into the tissue and survive there. And then it makes itself at home in ulcers and sites of inflammation and prevents those areas from healing.”

The findings suggest that eliminating the fungus might restore normal wound healing and shorten flare-ups. While the drug amphotericin B was effective at eliminating the fungus in mouse studies, it is not widely used in people because it can only be given intravenously. The researchers are working with chemists to develop an effective antifungal that can be taken by mouth. They also are studying whether there is a link between diet and the amount of the fungus in people’s digestive tracts.

“Crohn’s disease is fundamentally an inflammatory disease, so even if we figured out how to improve wound healing, we wouldn’t be curing the disease,” Jain said. “But in people with Crohn’s, impaired wound healing causes a lot of suffering. If we can show that depleting this fungus in people’s bodies – either by dietary changes or with antifungal medications – could improve wound healing, then it may affect the quality of life in ways that we’ve not been able to do with more traditional approaches.”

Jain U, Ver Heul AM, Xiong S, Gregory MH, Demers EG, Kern JT, Lai CW, Muegge BD, Barisas DAG, Leal-Ekman JS, Deepak P, Ciorba MA, Liu TC, Hogan DA, Debbas P, Braun J, McGovern DPB, Underhill DM, Stappenbeck TS. Debaryomyces is enriched in Crohn’s disease intestinal tissue and impairs healing in mice. Science. March 12, 2021. DOI: 10.1126/science.abd0919

The study was supported by the Crohn’s & Colitis Foundation; Lawrence C. Pakula; IBD Innovation; the National Institutes of Health (NIH), grant numbers AT009741, AI127548, DK125296 and NIH DK46763; the U.S. Department of Veterans Affairs, grant number IK2BX004909-01; and the American College of Gastroenterology.

Washington University School of Medicine’s 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.

Tamara covers infectious diseases, molecular microbiology, neurology, neuroscience, surgery, the Institute for Informatics, the Division of Physician-Scientists and the MSTP program. She holds a double bachelor's degree in molecular biophysics & biochemistry and in sociology from Yale University, a master's in public health from the University of California, Berkeley, and a PhD in biomedical science from the University of California, San Diego. She joined WashU Medicine Marketing & Communications in 2016. She has received three Robert G. Fenley writing awards from the American Association of Medical Colleges: a bronze in 2020 for "Mind’s quality control center found in long-ignored brain area," a silver in 2022 for "Mice with hallucination-like behaviors reveal insight into psychotic illness," and a bronze in 2023 for "Race of people given Alzheimer’s blood tests may affect interpretation of results." Since January of 2024, Tamara has been writing under the name Tamara Schneider.